Aclaris Therapeutics (ACRS) Tops Q1 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $2 million versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Deutsche Bank monitors UK auto sales as Chinese exports grow
• Piper Sandler Reiterates Overweight Rating on Patterson-UTI Energy (PTEN)
• Zurn Water Solutions (ZWS) Reiterated at Buy by Stifel on New Product Development Momentum